Authors
Latest:
Kara Cossis, PA-C, MPH, on the role of APPs in genetic testingAPPs can help in introducing genetic testing and in the interpretation of results, according to Kara Cossis, PA-C, MPH.
Latest:
What steps can physicians take to overcome barriers to health equity?“Things we have control over are ourselves, our care team, and to some extent, our care model,” said Sarah Candler, MD.
Latest:
Expert shares anticipated research directions for PSMA-PET in prostate cancer"I would basically look at these 3 things as the major things to be coming up," says Jitesh Dhingra, MD, FRCEM.
Latest:
177Lu-PSMA-617 prolongs rPFS in taxane-naïve mCRPC, benefit greater with prior abiraterone vs enzalutamideLutetium Lu 177 vipivotide tetraxetan improved rPFS vs switching to abiraterone acetate or enzalutamide in patients with taxane-naïve mCRPC who had progressed on prior abiraterone or enzalutamide. Outcomes were better, however, in patients who initially received abiraterone.
Latest:
The role of surgery continues to evolve in seminoma"RPLND is an attractive option for those who prefer to avoid chemotherapy," write Jiping Zeng, MD; Timothy A. Masterson, MD; and Clint Cary, MD, MPH, MBA.
Latest:
Potential Impact of PET/CT Imaging on Improving Patient CareNeal Shore, MD, FACS, and Brian Shuch, MD, provide closing thoughts on the potential of PET/CT imaging to improve patient care in kidney cancer.
Latest:
Current Shortcomings in the Modern Urology Practice Management LandscapeA urologist practicing in California defines the remaining general and region-specific challenges he faces in managing his practice and his hopes for future solutions.
Latest:
Managing Biochemical Recurrence in Prostate Cancer: Risk Stratification and Treatment DecisionsPanelists discuss how management options for nonmetastatic castration-sensitive prostate cancer (nmCSPC) include active surveillance, radiotherapy, and systemic therapy, with recommendations influenced by factors such as tumor volume, prostate-specific antigen (PSA) doubling time, and patient life expectancy, particularly for those with high-volume symptomatic disease.
Latest:
Closing Thoughts on the Impact of PSMA-PET Imaging in Prostate CancerExperts summarize how the use of PSMA-PET imaging has impacted the field to date and share their hopes for the future.
Latest:
Continued Advances and Unmet Needs in PSMA-Based Imaging for Prostate CancerExperts Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, consider the continued impact of PSMA PET imaging on prostate cancer management and emerging modalities that could revolutionize patient care.
Latest:
Balancing the benefits and risks of AI in health care“The potential benefits of incorporating AI into health care are numerous but like every technology, AI comes with risks that must be managed if the benefits of these tools are to outweigh the potential costs,” writes cybersecurity expert Jon Moore.
Latest:
Expert shares tips for safeguarding your practice when using telehealthHealth care practitioners utilizing telemedicine, regardless of the modality, must be cognizant of the many pitfalls of violating the rules regulating patient confidentiality as established by federal and state privacy laws.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
The safety and oncologic benefits of transperineal vs transrectal MRI-guided prostate biopsy"These studies, taken together, offer important insight into the direction we should be heading in prostate cancer diagnosis: toward a targeted-only TP biopsy," write Tarik Benidir, MD, and Zeyad Schwen, MD.
Latest:
UTI vaccine shows efficacy, safety in men and women"Overall, this vaccine is safe in the long term and our participants reported having fewer UTIs that were less severe," says Bob Yang, MBBS, FRCS.
Latest:
Race-based adjustment of eGFR: Current opinions and impact on urologic oncology“As other factors such as access to care, socioeconomic conditions, patient preference, and other unknown confounders might have played a role in the observed disparity, it is still unclear whether overestimating the postoperative eGFR of Black patients contributes to the lower use of nephron-sparing approaches in this population,” the authors write.
Latest:
Update on advanced imaging in prostate cancerAdvances allow for more accurate detection of metastatic disease.
Latest:
UroView: Gallium 68 PSMA–Targeted PET Imaging in Prostate Cancer: Staging and OutcomesThis article features insights from Phillip Kuo, MD, PhD, and Andre Abreu, MD, on gallium 68 PSMA-targeted PET imaging in prostate cancer.
Latest:
Optimizing Care Collaboration in Advanced Prostate CancerExplore strategies for seamless coordination between urologists and medical oncologists to ensure uninterrupted, patient-focused care in prostate cancer treatment.
Latest:
Medical software should be chosen based on your practice’s life cycle stageAt each stage, health care providers have different priorities and goals, and the choice of medical software solutions should be made accordingly.
Latest:
The current state of adjuvant radiotherapy post prostatectomy: 3 take-home messages"If your practice does not closely monitor patients and send them for early salvage radiotherapy when their PSA is 0.1 or 0.2 ng/mL, it is likely that adjuvant radiotherapy is superior," Daniel E. Spratt, MD, writes.
Latest:
Presentation, diagnosis, and management of a rare case of urachal adenocarcinoma"Urachal carcinoma is a rare and aggressive malignancy. The low incidence of the disease results in limited large-scale clinical trials that could provide standardized guidelines for its diagnosis and management," write Christopher Pieczonka, MD, and Peter Fioramonti, BS.
Latest:
Subgroup data sustain enzalutamide PFS benefit in nmCRPCNo new safety signals were reported with the androgen receptor pathway inhibitor.
Latest:
Continued Advances and Unmet Needs in PSMA-Based Imaging for Prostate CancerExperts Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, consider the continued impact of PSMA PET imaging on prostate cancer management and emerging modalities that could revolutionize patient care.
Latest:
Immune cell discovery offers new potential for cancer immunotherapyWinship study paves the way for more patients to benefit from future immunotherapies.
Latest:
Minimizing incontinence after radical prostatectomy: Lessons learned"I've worked in 3 different countries, I've seen dozens of people doing robotic radical prostatectomy...so my current practice is kind of a “best of” what I have seen and learned," says Ricardo Soares, MD.
Latest:
Neoadjuvant combo boosts MRD negativity rates in high-risk prostate cancerAdding apalutamide to the hormone therapy degarelix in the neoadjuvant setting increased the likelihood of achieving minimal residual disease negativity in patients with high-risk prostate cancer after radical prostatectomy.
Latest:
Physician Commentary: Do EHR upgrades really enhance patient care?"Clinicians, now more than ever, have many data entry duties. The clinical encounter’s efficiency is dictated by the ease of the EHR," write Jesse D. Bracamonte, DO, FAAFP, and Michael Underhill, DO.
Latest:
Case review: An incidentally discovered renal massAn expert panel discusses the case of a 65-year-old Caucasian male who is noted to have an incidental 3-cm right renal mass, enhancing on a contrasted CT scan as part of a routine follow-up for his metastatic castration-resistant prostate cancer, diagnosed in 2017 and currently undergoing therapy.
Latest:
Expert explains how to fully optimize EHRsRecent advances in technology make it possible to access and harness the vast amounts of clinical data EHRs have produced.
